Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jul 31, 2023 12:00pm
281 Views
Post# 35564890

Let’s just say the Q2 cc will be interesting

Let’s just say the Q2 cc will be interesting The bought deal?
Something they have done before. Was 2018 I believe.
This is the first time in a very long time, they have done "Only in Canada" deal.
Certainly not what I expected, although was in concept when they started coverage with that firm.
We can speculate until the sun goes down as to motivation, plans opportunities?
Good or bad, neither can be verified.
Obviously a 20% hair cut in one morning not good news.
Even @ that. The $15million is not enough to complete a phase 3 trial, let alone 2.trials.
This does howevr create a hypothetical floor for the price.
Like I said, the Q2 update hopefully shines some light on this financing.
They said, an answer regarding the PanCan offer for phase 3 inclusion would be within 90 days.
obviously the bought deal is part of that  process.
One thing for sure, with Onc expect the unexpected.


<< Previous
Bullboard Posts
Next >>